Skip to content
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why MVP wants to push fresher care-gap data into EMRs

Why MVP wants to push fresher care-gap data into EMRs

MVP Health Care, a nonprofit insurer in New York and Vermont, built Arcadia-based provider dashboards that combine ADT alerts, care gaps, utilization and pharmacy data. Timing drives the design. Its next step, delivering care gaps inside provider EMRs, should move fastest with practices that already exchange data through Arcadia.

  • 01For a quality measure on a seven-day clock, a payer report that runs a few months behind arrives after the deadline it was meant to help with.
  • 02The quickest EMR integrations for a regional payer are likely with practices already sharing data on the same platform through Medicare ACOs or other payers. Practices new to that kind of exchange need trust built in both directions first.
  • 03A useful test for any payer’s provider analytics: does a service completed last week drop off the care-gap list, or does the practice still call the patient again?

Nov 13, 2026

Humana's $2.8B BlackRock deal lets it buy back CenterWell clinics starting in 2028

Humana's $2.8B BlackRock deal lets it buy back CenterWell clinics starting in 2028

BlackRock's $2.8 billion buys majority ownership of a joint venture holding about 150 CenterWell clinics, replacing WCAS as Humana's outside investor. CenterWell keeps a minority stake and keeps running the clinics. The terms set a timeline: two years of expected growth spending, an option for Humana to buy clinics back from 2028, and a BlackRock right to start a sale of any clinics still in the venture at the end of 2033, with CenterWell getting the first offer. The deal is expected to close in the fourth quarter, subject to regulatory approvals.

  • 01BlackRock's $2.8 billion buys majority ownership of about 150 CenterWell clinics, while Humana keeps day-to-day management and an option to repurchase clinics starting in 2028.
  • 02The 2028 buyback and 2033 sale terms apply to the roughly 150 clinics in the new joint venture. CenterWell Senior Primary Care runs 250 clinics in total.
  • 03The deal’s lower-cost-of-capital claim will be tested after closing—first by how the venture deploys new capital over the next two years to support clinics, open locations and pursue acquisitions, and then by Humana’s 2028 decision on whether to start buying clinics back.

Nov 12, 2026

Healthcare AI should give doctors attention back, not shorter visits

Healthcare AI should give doctors attention back, not shorter visits

Healthcare organizations should deploy AI to give clinicians back attention and capacity for better decisions, not simply shorten visits. Landry argues AI should fit into existing workflows with insights appearing at the right time, and that organizations should set clear governance and automation boundaries before deployment and measure what changes for patients, clinicians and the organization.

  • 01AI success in healthcare should expand clinician capacity for thoughtful care, not optimize for visit speed; a three-minute appointment is not patient-centered innovation.
  • 02Design AI into workflows clinicians already use with insights appearing at the right moment, making adoption a workflow problem rather than a training problem.
  • 03Set automation boundaries before deploying AI, specifying what it may do alone, what it recommends for clinician decision-making, and what requires explicit human control and accountability.

Nov 11, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512